Martin SoucÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5567608/publications.pdf

Version: 2024-02-01

42	2,064	257450	265206
papers	citations	24 h-index	42 g-index

42	42	42	3484
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Two-step formulation of magnetic nanoprobes for microRNA capture. RSC Advances, 2022, 12, 7179-7188.	3.6	3
2	Highlighting the efficiency of ultrasoundâ€based emulsifierâ€free emulsions to penetrate reconstructed human skin. International Journal of Cosmetic Science, 2022, , .	2.6	2
3	Monitoring water content in NADES extracts from Spirulina biomass by means of ATR-IR spectroscopy. Analytical Methods, 2022, , .	2.7	1
4	Estimating the Analytical Performance of Raman Spectroscopy for Quantification of Active Ingredients in Human Stratum Corneum. Molecules, 2022, 27, 2843.	3.8	9
5	Homogeneous distribution of fatty esterâ€based active cosmetic ingredients in hydrophilic thin films by means of nanodispersion. International Journal of Cosmetic Science, 2020, 42, 512-519.	2.6	8
6	Freezing Weakens the Barrier Function of Reconstructed Human Epidermis as Evidenced by Raman Spectroscopy and Percutaneous Permeation. Pharmaceutics, 2020, 12, 1041.	4.5	9
7	gH625 Cell-Penetrating Peptide Promotes the Endosomal Escape of Nanovectorized siRNA in a Triple-Negative Breast Cancer Cell Line. Biomacromolecules, 2019, 20, 3076-3086.	5.4	20
8	Qualitative and Quantitative Study of the Potential of Lipid Nanocapsules of One Hundred Twenty Nanometers for the Topical Administration of Hydrophobic Molecules. Journal of Pharmaceutical Sciences, 2016, 105, 3191-3198.	3.3	12
9	On the interaction of alginate-based core-shell nanocarriers with keratinocytes in vitro. Colloids and Surfaces B: Biointerfaces, 2016, 142, 272-280.	5.0	14
10	Novel alginate-based nanocarriers as a strategy to include high concentrations of hydrophobic compounds in hydrogels for topical application. Nanotechnology, 2015, 26, 255101.	2.6	31
11	Analysis of doxorubicin distribution in MCF-7 cells treated with drug-loaded nanoparticles by combination of two fluorescence-based techniques, confocal spectral imaging and capillary electrophoresis. Analytical and Bioanalytical Chemistry, 2015, 407, 3425-3435.	3.7	11
12	Colloidal stability and thermo-responsive properties of iron oxide nanoparticles coated with polymers: advantages of Pluronic^{Â®}F68â€“PEG mixture. Nanotechnology, 2013, 24, 395605.	2.6	11
13	Design strategies of hybrid metallic nanoparticles for theragnostic applications. Nanotechnology, 2013, 24, 432002.	2.6	26
14	Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. Journal of Controlled Release, 2013, 169, 48-61.	9.9	120
15	Pegylated magnetic nanocarriers for doxorubicin delivery: A quantitative determination of stealthiness in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 498-505.	4.3	62
16	Magnetic Nanocarriers of Doxorubicin Coated with Poly(ethylene glycol) and Folic Acid: Relation between Coating Structure, Surface Properties, Colloidal Stability, and Cancer Cell Targeting. Langmuir, 2012, 28, 1496-1505.	3.5	111
17	A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting. International Journal of Pharmaceutics, 2012, 423, 16-25.	5.2	101
18	Doxorubicin delivered to MCF-7 cancer cells by superparamagnetic iron oxide nanoparticles: effects on subcellular distribution and cytotoxicity. Journal of Nanoparticle Research, 2011, 13, 959-971.	1.9	33

#	Article	IF	Citations
19	Synthesis and Evaluation of Novel Biocompatible Super-paramagnetic Iron Oxide Nanoparticles as Magnetic Anticancer Drug Carrier and Fluorescence Active Label. Journal of Physical Chemistry C, 2010, 114, 5850-5858.	3.1	53
20	Poly(ethylene glycol)-stabilized silver nanoparticles for bioanalytical applications of SERS spectroscopy. Analyst, The, 2009, 134, 1868.	3.5	82
21	Novel method of doxorubicinâ€“SPION reversible association for magnetic drug targeting. International Journal of Pharmaceutics, 2008, 363, 170-176.	5.2	133
22	The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications. Nanotechnology, 2008, 19, 465608.	2.6	113
23	On the Interaction of Doxorubicin with Oleate Ions: Fluorescence Spectroscopy and Liquid-Liquid Extraction Study. Chemical and Pharmaceutical Bulletin, 2007, 55, 1006-1010.	1.3	26
24	Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 31-38.	4.3	95
25	Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 488-492.	4.3	169
26	Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. International Journal of Nanomedicine, 2007, 2, 541-50.	6.7	95
27	Development and characterization of sub-micron poly(d,l-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles. International Journal of Pharmaceutics, 2005, 302, 187-196.	5.2	80
28	Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy. Analyst, The, 2005, 130, 1395.	3.5	304
29	New procedure for selective extraction of polycyclic aromatic hydrocarbons in plants for gas chromatographicâ€“mass spectrometric analysis. Journal of Chromatography A, 2002, 958, 1-7.	3.7	44
30	Analysis of anions in aqueous samples by ion chromatography and capillary electrophoresis. Journal of Chromatography A, 1999, 852, 487-498.	3.7	10
31	Effect of chronic trypanosomiasis on the bioavailability of Î±-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. Parasitology Research, 1997, 83, 386-389.	1.6	3
32	Daily validation procedure of chromatographic assay using gaussoexponential modelling. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 959-970.	2.8	9
33	Monitoring of an experimental red blood cell pathology with gravitational field-flow fractionation. Biomedical Applications, 1992, 579, 73-83.	1.7	45
34	Pitfalls in the choice of isotherms for the calculation of band profiles in preparative chromatography. Journal of Chromatography A, 1991, 537, 497-506.	3.7	4
35	Prediction of single and binary profiles in overloaded elution chromatography using various semi-ideal models. Journal of Chromatography A, 1991, 556, 205-218.	3.7	30
36	Effect of sample viscosity in high-performance size-exclusion chromatography and its control. Journal of Chromatography A, 1991, 550, 705-719.	3.7	54

#	Article	IF	Citations
37	Aligned fiber columns for size-exclusion chromatography. Journal of Chromatography A, 1990, 506, 303-317.	3.7	33
38	Comparison of the results obtained with different models for the simulation of preparative chromatography. Computers and Chemical Engineering, 1990, 14, 1435-1443.	3.8	31
39	A practical description of retention in reversed phase chromatography using four parameters. Chromatographia, 1989, 27, 5-14.	1.3	33
40	Theoretical study of multi-component interferences in non-linear chromatography. Journal of Chromatography A, 1989, 484, 103-124.	3.7	13
41	Sample size and retention values in high-performance liquid chromatography of biological and synthetic polymers. Journal of Chromatography A, 1988, 458, 79-92.	3.7	18
42	Polar bonded phases with adjusted hydrophobicity for hydrophobic interaction chromatography of proteins. Fresenius Zeitschrift FÃ¼r Analytische Chemie, 1987, 327, 34-34.	0.8	3